University of Wisconsin
School of Medicine and Public Health

Maha Mohamed, MD

Associate Professor (CHS)


MADISON, WI 53705-2281


  • University of Khartoum, Faculty of Medicine, Khartoum, Sudan – MD 
  • Mary Imogene Bassett Hospital/Columbia University, Cooperstown, New York – Residency in Internal Medicine  
  • Mary Imogene Bassett Hospital/Columbia University – Chief Resident  
  • George Washington University, Washington, District of Columbia – Fellowship in Geriatrics  
  • University of Maryland School of Medicine, Baltimore, Maryland – Fellowship in Nephrology  
  • University of California School of Medicine San Francisco, San Francisco, California – Fellowship in Transplant Nephrology 

Professional Activities

Dr. Maha Mohamed is a faculty member in the Division of Nephrology within the Department of Medicine. She is the Director of the Renal Transplant Fellowship Program and is involved in medical education. She also serves as the Director of Equity and Inclusion Curriculum for the UW School of Medicine and Public Health (SMPH) and is the Chair of the Health Equity Activation Team for SMPH. Dr. Mohamed is an active member of the American Society of Transplantation, serving as a member of their Transplant Nephrology Fellowship Training Accreditation Program Review Committee and Women’s Health Community of Practice, and a member of the Banff Subcommittee workgroup where she helps define guidelines on Post-Transplant recurrent Glomerular Disease. Dr. Mohamed has been recognized for her outstanding clinical work with numerous division and UW health awards. 

Clinical Specialties

Dr. Mohamed's special interests include renal transplantation outcomes, specifically evaluating modifiable predictors to improve kidney transplant survival in highly sensitized ESRD patients. 

Research Interests

View Dr. Maha Mohamed's publications on PubMed

Dr. Mohamed’s research interests include observing outcomes of desensitized recipients after renal transplantation, evaluating predictors to improve long-term allograft survival, and studying treatment modalities adopted to maximize the survival of the renal allograft after antibody mediated rejections.